Skip to main content

Orwell on Hitler's "Struggle"

Image result for hitler paintings


The publisher Hurst & Blackett brought out an English language edition of AH's book, Mein Kampf, in 1939.

It was, as George Orwell says in the review to which I'll link you in a moment, edited in an appeasementist spirit: 'see? Hitler's not so bad, maybe we can all get along.' A year later, the same publishers re-issued it, apparently with new prefatory material etc. because Britain and Germany had in the meantime gone to war.

I think Orwell's review, written in response to the re-issuance, holds up very well through all the intervening decades. I especially like the summary of the world Hitler wanted: " a horrible brainless empire in which, essentially, nothing ever happens except the training of young men for war and the endless breeding of fresh cannon-fodder."

Here's the URL:

https://worldview.carnegiecouncil.org/archive/worldview/1975/07/2555.html/_res/id=File1/v18_i007-008_a010.pdf

Comments

  1. I am struck by Orwell's prediction that Hitler would attack Russia, despite what he calls the Russo-German Pact. Orwell wrote this in March 1940, and the Nazi attack on Russia occurred in June 1941. I wonder if Orwell had unusual insight, or if many had made the same prediction by March 1940.

    ReplyDelete
  2. @Henry
    According to summaries of the bk I've seen, Hitler explicitly wrote in Mein Kampf about the need for Germany to expand to the east; Lebensraum, etc. So Orwell was prob. not alone in predicting this. Hitler had initially wanted to attack Russia in autumn 1940, before deciding he needed more time to prepare (see G. Wright, The Ordeal of Total War, pb. 1968, p.33).

    ReplyDelete

Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…